You are here: Industry Insights > Celgene

News List

Celgene Co-Founder Bags $23M for Johns Hopkins Spinout NexImmune biospace
January 03, 2018
NexImmune Raises $23 Million to Advance Endogenous Cellular ImmunoTherapy into Clinical Development
Celgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials biospace
January 02, 2018
Celgene announced back in October that it was discontinuing its GED-0301 (mongersen) program for Crohn’s disease. Now Celgene has worked out how much that decision is costing the company—$411 million.
Celgene Crashed After Follicular Lymphoma Regimen Failed Phase III biospace
December 25, 2017
Shares of Celgene plunged more than five points per share after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.
Cancer Research UK agrees largest drug discovery collab to date pharmafile
December 18, 2017
Cancer Research UK has announced that its subsidiary, Cancer Research Technology (CRT), and Celgene have agreed a drug discovery collaboration.
Why Pfizer Could and Should Scoop Up Celgene in 2018 biospace
December 06, 2017
Pfizer is no stranger to taking the big gambles—note the company’s attempts to buy AstraZeneca in 2014 and Allergan in 2016
Celgene hikes price of Revlimid to mask poor Q3 results pharmafile
October 30, 2017
Celgene posted its Q3 results and investors did not react well – shares plunged 16% immediately, after the biotech cut its guidance through to 2020.
Armo taps Celgene, GV for $67M to fuel late-phase I-O R&D fiercebiotech
August 31, 2017
Armo will use the money to run phase 2/3 trials in renal cell and non-small cell lung cancer.
With IBD market set for major growth, AbbVie stands to benefit: analyst fiercepharma
August 24, 2017
AbbVie's pipeline contains multiple prospects to treat inflammatory bowel disease.
Celgene opts not to acquire Sutro Biopharma for $1bn, reworks existing partnership pharmafile
August 14, 2017
Celgene has announced that it has chosen not to scoop up Sutro Biopharma, rejecting to take advantage of an option outlined in its $1 billion partnership struck in 2014 which would allow it to acquire the US biotech.
Celgene drops Sutro buyout option and refocuses deal on 4 I-O programs, freeing partner to pursue ne fiercebiotech
August 11, 2017
Celgene gained the Sutro buyout option after paying $95 million and committing to $1 billion more in 2014.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page